X

Drug Profile

EG 009

Alternative Names: EG-009

Latest Information Update: 04 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Evergreen Therapeutics
Class Anti-inflammatories
Mechanism of Action Cytokine inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Cytokine release syndrome

Most Recent Events

31 Jul 2024 Phase I clinical development in Cytokine release syndrome (In volunteers) is ongoing in USA (PO, Capsule) (Shenzhen Eglin Pharmaceutical pipeline, July 2024)
31 Jul 2024 phase-I development in Cytokine release syndrome (In volunteers) is ongoing in USA (IM, Injection) (Shenzhen Eglin Pharmaceutical pipeline, July 2024)
23 Oct 2020 Shenzhen Eglin Pharmaceutical has patent protection for EG 009 (Shenzhen Eglin Pharmaceutical pipeline, October 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com